IMR Press / FBE / Volume 4 / Issue 3 / DOI: 10.2741/E423

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Myeloid-derived suppressor cells: Therapeutic modulation in cancer

Show Less
1 Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905
2 Department of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905

*Author to whom correspondence should be addressed.


Front. Biosci. (Elite Ed) 2012, 4(3), 838–855;
Published: 1 January 2012

Improved understanding of the cellular and molecular basis of adaptive immunity has been realized over the past few decades, leading to the development of novel immunotherapeutic strategies capable of promoting host anti-tumor immunity. In order to achieve clinically meaningful results, further understanding of the mechanisms by which tumors suppress host immunity, and the development of therapeutic strategies which overcome tumor-associated immune suppression, will be necessary. Myeloid-derived cells with potent immunosuppressive properties are ubiquitous in human cancers. Improved mechanistic understanding of factors promoting their development, activation and mechanisms of immune suppression are being translated into novel therapeutic approaches, and will be summarized herein.

Myeloid-derived Suppressor Cell
T Cell
Nitric Oxide Synthase
Back to top